Temasek's GHX scores around $500m from Warburg, entering next phase of growth

The healthcare technology company is an example of Temasek’s quiet but quick penetration in the North American buyout market, which has grown from 0 percent to 17 percent of its net portfolio value as of March 2020.

DealsHealthcareFeaturedTop Stories